Press "Enter" to skip to content

SUSTAIN 9 Trial Success; Hormone Therapy & Alzheimer’s; ‘Diabulimia’

The GLP-1 RA semaglutide (Ozempic) — in combination with an SGLT-2 inhibitor — was superior for decreasing HbA1c levels versus placebo in the phase IIIb SUSTAIN 9 trial, Novo Nordisk announced this week.

Risk for Alzheimer’s may be slightly increased with systemic hormone therapy in postmenopausal women, a new study suggested, although there was no risk seen with vaginal estradiol. (The BMJ)

In other news, menopause may increase a women’s risk for experiencing chronic pain. “Changing levels of hormones around menopause have complex interactions with pain modulation and pain sensitivity, which may be associated with vulnerability to either the development or exacerbation of pain conditions,” commented JoAnn Pinkerton, MD, executive director of the North American Menopause Society. (Menopause)

Novo Nordisk has applied for an expanded indication for its fast-acting insulin aspart (Fiasp) to include children and adolescents.

A French court dismissed a lawsuit against Merck involving its hypothyroidism drug Levothyrox. Some 4,000 plaintiffs alleged they suffered new side effects after Merck reformulated the product. (Reuters)

A new eating disorder, dubbed diabulimia, is popping up among people with type 1 diabetes, in which patients skip insulin injections in order to lose weight. (The BMJ)

The thyroid eye disease treatment teprotumumab succeeded in a phase III study, Horizon Pharma announced. (Endpoints News)

Paul Stewart, MD, of University of Leeds in England, will take over as editor-in-chief of the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism next January.


last updated